Mumbai: Cadila Healthcare, the Zydus Cadilla Group flagship, has emerged as the frontrunner to acquire the generic sterile injectables business of Ahmedabad-headquartered Claris Lifesciences Ltd (CLL) trumping several domestic and global peers who ... India Brand Equity Foundation, 10 hours ago
Cadila Healthcare eyes Claris arm for Rs 3,400 crore - Economic Times, 1 day ago
Buy Cadila Healthcare; tgt of Rs 1920: Firstcall Research - Moneycontrol.com, 2 days ago
2 images for "zydus group"
A novel oral treatment regimen for patients suffering from Hepatitis C Zydus group has launched SoviHep, which will provide succour to more than 10 million patients who suffer from Hepatitis C in India. The therapy will be marketed by the ...Financial Express, 2 months ago Zydus Cadila Launches Generic Version of Gilead Sciences Hepatitis C drug in India Topnews.in, 2 months ago Zydus Cadila to present new clinical data on Lipaglyn at AACE meeting in USA PharmaBiz, 1 week ago Cadila spurts 4% at opening bell India Infoline, 2 months ago
Zydus Group enters collaboration with NIH for advancing Leishmaniasis research, donates US$ 2.40 lakh
Zydus Group's subsidiary Etna Biotech has entered a collaborative programme with the National Institute of Allergy and Infectious Diseases, part of the US National Institutes of Health (NIH) for advancing leishmaniasis research. Etna extended its ...PharmaBiz, 4 weeks ago Zydus Group to Donate USD 240,000 to The National Institutes of Health, USA for Advancing Leishmaniasis Research A.M. Best, 4 weeks ago Zydus donates $240,000 to National Institutes of Health,US NetIndia123.com, 4 weeks ago
AHMEDABAD: Zydus Cadila registered a net profit of Rs. 1151 crores for the year ended 31st March 2015 — up by 43% from Rs. 804 crores in the previous year. During the year, the company registered gross sales of Rs. 8658 crores, up by 20% from Rs.Times of India, 6 days ago Zydus Cadila Q4 net up 46%; revenues jump 16% Smart Investor, 1 week ago Zydus Cadila Q4 net profit up 46% Livemint.com, 1 week ago Cadila Healthcare consolidated net surges by 46% in Q4, dividend at 240% PharmaBiz, 1 week ago
has earlier worked with agencies such as Grey Worldwide, L&K Saatchi & Saatchi and Access Leo Burnett, Nairobi. DDB Mudra West has roped in Manoj Bhagat as group creative director. Bhagat joins the agency's Mumbai office from Greenapple Design, ...Agencyfaqs!, 1 week ago
Ahmedabad-based pharma major Zydus Cadila, which is planning to develop a medicine for patients suffering from fatty liver disease, is making a presentation on its novel drug Lipaglyn at the American Association of Clinical Endocrinologists (AACE) ...Business Standard India, 1 week ago
Zydus Hospital will soon open its second 550- bed super-specialty hospital in Ahmedabad with an investment of Rs 550 crore. Also it plans to invest Rs 1000 crore in Gujarat in coming 5-6 years. According to Pankaj Patel, founder, Zydus Hospitals, ...EHealth Magazine, 1 month ago Pankaj Patel shares details of soon-to-open Zydus Hospital in Ahmedabad DeshGujarat, 1 month ago
Pharmaceuticals major Zydus today said that its R&D subsidiary Etna Biotech will collaborate with US-based National Institute of Allergy and Infectious Diseases (NIAD) to develop a vaccine against visceral leishmaniasis (VL), known as Kala-Azar in ...Hindu Business Line, 4 weeks ago Zydus ties up with US-based research centre to develop vaccine Daily Excelsior.com, 4 weeks ago Zydus ties up with US-based RD centre to develop vaccine Moneycontrol.com, 4 weeks ago Zydus to tie up with US-based research centre to develop vaccine Financial Express, 4 weeks ago
Zydus Cadila and Gilead Sciences, Inc. have signed a non-exclusive licensing agreement which will allow the manufacture of sofosbuvir and the fixed-dose combination of ledipasvir/ sofosbuvir for distribution in 91 countries including India. The ...Indian-Commodity, 2 months ago Cadila Healthcare gains on announcing a collaborative program with the National Institute of Alle... Arihant Capital, 4 weeks ago Cadila Healthcare gains on inking non-exclusive licensing pact with Gilead Sciences Arihant Capital, 2 months ago
Pieris Pharmaceuticals Appoints Former Celgene and Sanofi Executive, Jean-Pierre Bizzari, M.D., to Its Board of Directors
FREISING, GERMANY Dr. Bizzari was the Executive Vice President, Group Head, Clinical Oncology Development at Celgene Corporation. Since joining Celgene in 2008, he directed the development and approval of a number of leading oncology products ...Digital Journal, 1 week ago Pieris Pharmaceuticals, Inc. (PIRS: OTCQB) | Pieris Pharmaceuticals to Present Data on Novel Anti-CD137 and HER2 Bispecific Immuno-Oncology Program at UBS Global Healthcare Conference OTC Markets, 3 days ago Pieris Pharmaceuticals to Present Data on Novel Anti-CD137 and HER2 Bispecific Immuno-Oncology Program at UBS Global Healthcare Conference RCL Advisors, 3 days ago PIERIS PHARMACEUTICALS : to Present Data on Novel Anti-CD137 and HER2 Bispecific Immuno-Oncology Program at UBS Global Healthcare Conference 4 Traders, 3 days ago
on your WebpageAdd Widget >Get your members hooked!